Eisai Company Top Insiders
| ESALF Stock | USD 30.50 0.50 1.67% |
Eisai employs about 11.3 K people. The company is managed by 10 executives with a total tenure of roughly 46 years, averaging almost 4.0 years of service per executive, having 1132.2 employees per reported executive. Examination of Eisai's management performance can provide insight into the company performance.
| Gary Hendler CEO Sr. VP, CEO of Eisai Europe Ltd and President of Eisai Europe Ltd and President of EMEA Region and President of Eisai Global Oncology Bus. Unit |
| Haruo Naito CEO CEO, Representative Corporate Officer and Director |
Eisai |
Eisai Management Team Effectiveness
Eisai's management efficiency ratios could be used to measure how well Eisai manages its routine affairs as well as how well it operates its assets and liabilities.Eisai Workforce Comparison
Eisai Co is rated # 2 in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is currently estimated at about 23,162. Eisai totals roughly 11,322 in number of employees claiming about 49% of equities under Drug Manufacturers—Specialty & Generic industry.
The company has Profit Margin (PM) of 0.04 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.01 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.01. Eisai Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Eisai Price Series Summation is a cross summation of Eisai price series and its benchmark/peer.
Eisai Notable Stakeholders
An Eisai stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Eisai often face trade-offs trying to please all of them. Eisai's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Eisai's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Gary Hendler | Sr. VP, CEO of Eisai Europe Ltd and President of Eisai Europe Ltd and President of EMEA Region and President of Eisai Global Oncology Bus. Unit | Profile | |
| Haruo Naito | CEO, Representative Corporate Officer and Director | Profile | |
| Kenta Takahashi | Sr. VP, Executive Director of Legal Department and General Counsel of Intellectual Property | Profile | |
| Tatsuyuki Yasuno | Executive Officer, Director of Corporate Planning & Strategy | Profile | |
| Sayoko Sasaki | Executive Officer, Director of PR, Manager of Global Access Strategies Office | Profile | |
| Yanhui Feng | Executive Officer, General Manager of Subsidiaries | Profile | |
| Nadeem Sarwar | President | Profile | |
| Yosuke Akita | Chief VP | Profile | |
| Teruyuki Masaka | VP Officer | Profile | |
| MD FAAN | VP Health | Profile |
About Eisai Management Performance
The success or failure of an entity such as Eisai often depends on how effective the management is. Eisai management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Eisai management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Eisai management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
It offers Aricept for the treatment of alzheimers diseasedementia with Lewy bodies Methycobal for the treatment of peripheral neuropathy and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan. Eisai operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 11322 people.
Eisai Workforce Analysis
Traditionally, organizations such as Eisai use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Eisai within its industry.Eisai Manpower Efficiency
Return on Eisai Manpower
| Revenue Per Employee | 66.8M | |
| Revenue Per Executive | 75.6B | |
| Net Income Per Employee | 4.2M | |
| Net Income Per Executive | 4.8B | |
| Working Capital Per Employee | 28M | |
| Working Capital Per Executive | 31.7B |
Complementary Tools for Eisai Pink Sheet analysis
When running Eisai's price analysis, check to measure Eisai's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eisai is operating at the current time. Most of Eisai's value examination focuses on studying past and present price action to predict the probability of Eisai's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eisai's price. Additionally, you may evaluate how the addition of Eisai to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |